# EDGAR Filing Document

**Accession Number:** 0001840877
**File Stem:** 0001213900-26-058429
**Filing Date:** 2026-5
**Character Count:** 16945
**Document Hash:** 2fa03d25d953ac073ad97c7cfe533fb1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-058429.hdr.sgml**: 20260518

**ACCESSION NUMBER**: 0001213900-26-058429

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260512

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260518

**DATE AS OF CHANGE**: 20260518

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Envoy Medical, Inc.
- **CENTRAL INDEX KEY:** 0001840877
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 861369123
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40133
- **FILM NUMBER:** 26993140

**BUSINESS ADDRESS:**
- **STREET 1:** 4875 WHITE BEAR PARKWAY
- **CITY:** WHITE BEAR LAKE
- **STATE:** MN
- **ZIP:** 55110
- **BUSINESS PHONE:** 651-361-8000

**MAIL ADDRESS:**
- **STREET 1:** 4875 WHITE BEAR PARKWAY
- **CITY:** WHITE BEAR LAKE
- **STATE:** MN
- **ZIP:** 55110

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Anzu Special Acquisition Corp I
- **DATE OF NAME CHANGE:** 20210115

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 12, 2026**

**ENVOY MEDICAL, INC.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40133** | **86-1369123** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **4875 White Bear Parkway<br> White Bear Lake, MN** | **55110** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**Registrant's telephone number, including area code: (877) 900-3277**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Class A Common Stock, par value $0.0001 per share | COCH | The Nasdaq Stock Market LLC |
| Redeemable Warrants, each whole Warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share | COCHW | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On May 12, 2026, Envoy Medical, Inc. (the "<u>Company</u>") held its 2026 Annual Meeting of Stockholders (the "<u>Annual Meeting</u>"). At the Annual Meeting, the Company's stockholders (the "<u>Stockholders</u>") approved (the "<u>Stockholder Approval</u>"): (i) an amendment to the Company's 2023 Equity Incentive Plan (the "<u>Equity Incentive Plan</u>") to authorize an additional 6,000,000 shares of the Company's Class A Common Stock, par value $0.0001 per share ("<u>Common Stock</u>"), for issuance under the Equity Incentive Plan (the "<u>Equity Plan Amendment</u>") and (ii) an amendment to the Company's 2023 Employee Stock Purchase Plan (the "<u>Employee Stock Purchase Plan</u>") to authorize an additional 1,200,000 shares of Common Stock for issuance under the Employee Stock Purchase Plan (the "<u>Purchase Plan Amendment</u>").

The Company's Board of Directors approved each of the Equity Plan Amendment and the Purchase Plan Amendment subject to Stockholder approval at the Annual Meeting. Each of the Equity Plan Amendment and the Purchase Plan Amendment became effective at the time of Stockholder Approval.

Copies of the Equity Plan Amendment and Purchase Plan Amendment are attached to this Current Report on Form 8-K as Exhibits 10.1 and 10.2, respectively, and are incorporated herein by reference. The material terms of the Equity Incentive Plan and Employee Stock Purchase Plan, as amended, are set forth in the Company's definitive proxy statement relating to the Annual Meeting filed with the Securities and Exchange Commission on April 2, 2026.

**Item 5.07 Submission of Matters to a Vote of Security Holders.** 

At the Annual Meeting:

&nbsp;&nbsp;&nbsp;&nbsp;1. The Company's stockholders elected two Class III director nominees, Brent T. Lucas and Susan J.
Kantor, to the Company's Board of Directors to hold office until the earlier of the 2029 annual meeting of stockholders, the election
of such director's successor, or such director's death, resignation or removal;

&nbsp;&nbsp;&nbsp;&nbsp;2. Stockholders ratified the appointment of EisnerAmper, LLP as the Company's independent registered
public accounting firm for the fiscal year ending December 31, 2026;

&nbsp;&nbsp;&nbsp;&nbsp;3. Stockholders approved, on a non-binding and advisory basis, the compensation of the Company's named
executive officers;

&nbsp;&nbsp;&nbsp;&nbsp;4. Stockholders approved an amendment to the Equity Incentive Plan to authorize an additional 6,000,000 shares
of Common Stock for issuance under such plan;

&nbsp;&nbsp;&nbsp;&nbsp;5. Stockholders approved an amendment to the Employee Stock Purchase Plan to authorize an additional 1,200,000 shares
of Common Stock for issuance under such plan; and

&nbsp;&nbsp;&nbsp;&nbsp;6. Stockholders approved, for the purposes of complying with Nasdaq Listing Rule 5635(d), the issuance
of warrants to purchase shares of the Common Stock, and the issuance of Class A Common Stock underlying such warrants, that were
issued in a transaction that was completed on February 12, 2026.

The voting results for each such matter were as follows:

&nbsp;&nbsp;&nbsp;&nbsp;1. Election of directors:

---

| | | | |
|:---|:---|:---|:---|
| Nominee: | For: | Withheld: | Broker Non-Votes: |
| Brent T. Lucas | 47216205 | 70530 | 655966 |
| Susan J. Kantor | 46961571 | 325164 | 655966 |

---

&nbsp;&nbsp;&nbsp;&nbsp;2. Ratification of the appointment of EisnerAmper, LLP as the Company's independent registered public
accounting firm for the fiscal year ending December 31, 2026:

<u>For:</u> <u>Against:</u> <u>Abstain:</u> <br> 47,933,597 3,434 5,670

&nbsp;&nbsp;&nbsp;&nbsp;3. Approval, on a non-binding and advisory basis, of the Company's named executive officer compensation:

---

| | | | |
|:---|:---|:---|:---|
| For: | Against: | Abstain: | Broker Non-Votes: |
| 47144585 | 110476 | 31674 | 655966 |

---

&nbsp;&nbsp;&nbsp;&nbsp;4. To approve an amendment to the Equity Incentive Plan.

---

| | | | |
|:---|:---|:---|:---|
| For: | Against: | Abstain: | Broker Non-Votes: |
| &nbsp;&nbsp;46,609,864 | &nbsp;&nbsp;624,758 | &nbsp;&nbsp;52,113 | &nbsp;&nbsp;655,966 |

---

&nbsp;&nbsp;&nbsp;&nbsp;5. To approve an amendment to the Employee Stock Purchase Plan.

---

| | | | |
|:---|:---|:---|:---|
| For: | Against: | Abstain: | Broker Non-Votes: |
| &nbsp;&nbsp;47,152,146 | &nbsp;&nbsp;86,804 | &nbsp;&nbsp;47,785 | &nbsp;&nbsp;655,966 |

---

&nbsp;&nbsp;&nbsp;&nbsp;6. Stockholders approved, for the purposes of complying with Nasdaq Listing Rule 5635(d), the issuance
of warrants to purchase shares of the Common Stock and the issuance of Common Stock underlying such warrants, that were issued in a transaction
that was completed on February 12, 2026.

---

| | | | |
|:---|:---|:---|:---|
| For: | Against: | Abstain: | Broker Non-Votes: |
| &nbsp;&nbsp;47,217,476.89 | &nbsp;&nbsp;42,625 | &nbsp;&nbsp;26,634 | &nbsp;&nbsp;655,966 |

---

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 10.1 | [Amended No. 1 to Envoy Medical, Inc. Amended and Restated 2023 Equity Incentive Plan](ea029135401ex10-1.htm) |
| 10.2 | [Amended No. 1 to Envoy Medical, Inc. 2023 Employee Stock Purchase Plan](ea029135401ex10-2.htm) |
| 104 | Cover Page Interactive Data File (embedded with the Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **ENVOY MEDICAL, INC.** | **ENVOY MEDICAL, INC.** |
| May 18, 2026 | By: | /s/ Brent T. Lucas |
|  |  | Brent T. Lucas |
|  |  | Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**Envoy Medical, Inc.**

**Amendment No. 1 to** 

**Amended and Restated<br> 2023 Equity Incentive Plan**

**Amendment No. 1 Approved by the Board of Directors March 20, 2026<br> Amendment No. 1 Approved by the Stockholders May 12, 2026**

This Amendment No. 1 (this "***Amendment***") amends the Amended and Restated Envoy Medical, Inc. 2023 Equity Incentive Plan (the "***Plan***") effective as of May 12, 2026. All capitalized terms used but not defined in this Amendment shall have the meanings provided in the Plan.

**1.** **Amendment to Section 2.** Section 2 of the Plan is hereby
fully replaced and superseded with the following text:

---

| | |
|:---|:---|
| "2. | **Shares Subject to the Plan.** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) **Share Reserve.** Share Reserve. Subject to adjustment
in accordance with Section 2(c) and any adjustments as necessary to implement any Capitalization Adjustments, the aggregate number of
shares of Common Stock that may be issued pursuant to Awards will be 10,000,000 shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) **Aggregate Incentive Stock Option Limit.** Notwithstanding
anything to the contrary in Section 2(a) and subject to any adjustments as necessary to implement any Capitalization Adjustments, the
aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options is 10,000,000
shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) **Share Reserve Operation.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) **Limit Applies to Common Stock Issued Pursuant to Awards.** For clarity, the Share Reserve is a limit on the number of shares of Common Stock that may be issued pursuant to Awards and does not
limit the granting of Awards, except that the Company will keep available at all times the number of shares of Common Stock reasonably
required to satisfy its obligations to issue shares pursuant to such Awards. Shares may be issued in connection with a merger or acquisition
as permitted by, as applicable, Nasdaq Listing Rule 5635(c), NYSE Listed Company Manual Section 303A.08, NYSE American Company Guide
Section 711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) **Actions that Do Not Constitute Issuance of Common Stock and Do Not Reduce Share Reserve.** The following actions do not result in an issuance of shares under the Plan and accordingly do not
reduce the number of shares subject to the Share Reserve and available for issuance under the Plan: (1) the expiration or termination
of any portion of an Award without the shares covered by such portion of the Award having been issued; (2) the settlement of any portion
of an Award in cash (*i.e.*, the Participant receives cash rather than Common Stock); (3) the withholding of shares that would otherwise
be issued by the Company to satisfy the exercise, strike or purchase price of an Award; or (4) the withholding of shares that would otherwise
be issued by the Company to satisfy a tax withholding obligation in connection with an Award.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) **Reversion of Previously Issued Shares of Common Stock to Share Reserve.** The following shares of Common Stock previously issued pursuant to an Award and accordingly initially deducted
from the Share Reserve will be added back to the Share Reserve and again become available for issuance under the Plan: (1) any shares
that are forfeited back to or repurchased by the Company because of a failure to meet a contingency or condition required for the vesting
of such shares; (2) any shares that are reacquired by the Company to satisfy the exercise, strike or purchase price of an Award; and
(3) any shares that are reacquired by the Company to satisfy a tax withholding obligation in connection with an Award."

2. **No Other Amendments**. Except as expressly set forth in
this Amendment, the Plan shall remain in full force and effect with no changes.

## Exhibit 10.2

**Exhibit 10.2**

**Envoy Medical, Inc.**

**Amendment No. 1 to** 

**2023 Employee Stock Purchase Plan**

**Amendment No. 1 Approved by the Board of Directors March 20, 2026<br> Amendment No. 1 Approved by the Stockholders May 12, 2026**

This Amendment No. 1 (this "***Amendment***") amends the Envoy Medical, Inc. 2023 Employee Stock Purchase Plan (the "***Plan***") effective as of May 12, 2026. All capitalized terms used but not defined in this Amendment shall have the meanings provided in the Plan.

**2.** **Amendment to Section 12.** Section 12 of the Plan is hereby
fully replaced and superseded with the following text:

---

| | |
|:---|:---|
| "12. | **Stock.** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Subject to adjustment upon changes in capitalization of the
Company as provided in Section 17, the maximum number of shares of Common Stock which shall be made available for sale under the Plan
shall be 4,300,000 shares. If the Administrator determines that on a given Exercise Date the number of shares with respect to which Options
are to be exercised may exceed: (x) the number of shares then available for sale under the Plan; or (y) the number of shares available
for sale under the Plan on the Offering Date(s) of one or more of the Offer Periods in which such Exercise Date is to occur, the Administrator
may make a pro rata allocation of the shares remaining available for purchase on such Offering Dates or Exercise Date, as applicable,
and shall either continue the Offer Period then in effect or terminate any one or more Offer Periods then in effect pursuant to Section
18, below. Such allocation method shall be "bottom up," with the result that all Option exercises for one (1) share shall
be satisfied first, followed by all exercises for two (2) shares, and so on, until all available shares have been exhausted. Any amount
remaining in a Participant's payroll account following such allocation shall be returned to the Participant and shall not be carried
over to any future Purchase Period or Offer Period, as determined by the Administrator.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) A Participant will have no interest or voting right in shares
covered by the Participant's Option until such shares are actually purchased on the Participant's behalf in accordance with
the applicable provisions of the Plan. No adjustment shall be made for dividends, distributions or other rights for which the record
date is prior to the date of such purchase.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Shares to be delivered to a Participant under the Plan will
be registered in the name of the Participant."

2. **No Other Amendments**. Except as expressly set forth in
this Amendment, the Plan shall remain in full force and effect with no changes.